Starting salary is in the range of £38,607 to £41,718 per annum inclusive dependent on relevant postdoctoral experience. Future progression is based on annual performance review. If the candidate has not yet been awarded their PhD, the starting salary will be at £32,844 until the successful completion of their viva.
We are seeking a creative and motivated Postdoctoral Training Fellow to study the emergence, prevention and treatment of PARP inhibitor resistance in breast and ovarian cancer. PARP inhibitor resistance can emerge via a number of routes, but the most well-described clinical mechanism is via reversion mutations that restore the function of BRCA1/2 (Pettitt et al., Cancer Discovery 2020; reversions.icr.ac.uk).
The proposed project aims to experimentally characterise BRCA reversion mutations, to determine whether certain pathogenic mutations confer different risks of reversion, and whether genetic background, treatment regime or other interventions can modify reversion risk. This will entail the use of high throughput “tiling” CRISPR mutagenesis (Pettitt et al. Nat Comms 2018), insights from computational analysis of reversions (Pettitt et al. Cancer Discovery 2021) and small molecule DDR inhibitors which may modulate reversion development (Zatreanu et al. Nat Comms 2021). Models used will include cell lines, PDX, PDO and syngeneic mouse models, as well as analysis of sequencing data from human biopsies and ctDNA. The post would suit a candidate with strong CRISPR functional genomics, high throughput cell culture and/or DDR experience.
The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 10 years
The Gene Function Laboratory, led by Prof. Chris Lord, focuses upon identifying and understanding tumour specific dependencies, such as synthetic lethal effects, as a means to design novel approaches to treating cancer. We have made major advances in identifying synthetic lethal interactions involving, for example, PARP inhibitors (Farmer et al Nature (2005), Edwards et al Nature (2008), Bajrami et al, Cancer Research (2014)), ATR inhibitors (Williamson et al, Nature Communications (2016)) and ROS1 inhibitors (Bajrami et al, Cancer Discovery (2018)). We aim to generate pre-clinical information that can inform the design of clinical trials and the identification of novel targets for drug discovery programmes.
The Breast Cancer Now Toby Robins Research Centre at the ICR is the first centre in the UK entirely devoted to breast cancer research. Our goal is to advance research into the causes, diagnosis and treatment of breast cancer.
We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact firstname.lastname@example.org
About The Institute of Cancer Research
Why work for us?
As a member of staff, you’ll have exclusive access to a range of staff benefits.
The ICR is committed to supporting overseas applicants applying for roles, please click here to find out further information.
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. Further information about working at the ICR can be found here.
We look forward to receiving applications from all candidates, wherever in the world they are currently based. We will select those who display the potential to become, or to support, the world leading cancer researchers of the future based on their application and performance at interview. However, we particularly welcome British applicants from black and ethnic minority backgrounds, as they are under-represented within the ICR and nationwide in STEM roles.
|Job Category||Internship and training|